21comM

The Best Performing ISA ETFs This Month

Equities 3 minutes to read
Neil Wilson
Neil Wilson

Investor Content Strategist

Note: This is marketing material. This article is not investment advice, capital is at risk.

Key Points

  • Biotechnology ETFs top the charts in October
  • Blockchain, Space and Hydrogen technologies see momentum
  • South Korea leads the way as KOSPI tops global equity indices

October has seen a bit of rockiness in global equity markets – so we thought it a good time to check in to see which sectors are performing well by looking at the top ETFs of the last month. (These are equity ETFs screened for ISA eligibility).

Top of the tree with a nearly 20% 1m gain is the WisdomTree BioRevolution ETF.  Performance has been driven by a 56% gain for top holdingIntella Therapeutics, and a more than 350% jump for its second-largest holding, uniQure, which have both reported progress with respective gene therapy programmes. Other significant holdings include CRISPR Therapeutics, Stoke Therapeutics and Sana Biotechnology.

Boasting a similar profile of holdings and performance, the ARK Genomic Revolution ETF is the second best performer. Its main holding is gene-editing firm CRISPR, at more than 8% of the fund. Tempus AI and Intella Therapeutics each account for around 7% of the fund’s weight, with Recursion Pharmaceuticals and Personalis rounding out the top five holdings.

Sticking with this theme in third place is the Global X Genomics & Biotechnology ETF, which has risen almost 18%. Its largest holding is Alnylam Pharmaceuticals, which has doubled its market cap this year. CRISPR is the second largest holding in the fund.

Fourth we can look to crypto markets despite the downturn for bitcoin in recent days – the Invesco CoinShares Global Blockchain ETF is number four on the charts. Its main holdings are among the best-known names in the space – Cipher Mining, IREN, Bitfarms, Cleanspark and Galaxy Digital.

Donald Trump’s focus on rare earth metals has sent stocks in the sector higher and thereby lifted the VanEck Rare Earth and Strategic Metals ETF into fifth place. MP Materials, which the US administration took a stake in this year, is the top holding of this strategic fund. Lynas, Lithium Americas, Albemarle and China Northern Rare Earth are among the other major holdings.

Global X Hydrogen ETF – boasting major holdings in Bloom Energy and Plug Power - was another notably strong performer that reflects global megatrends.

We’re getting into retail favourites next with the VanEck Space Innovators ETF. Its performance is impressive since AST SpaceMobile, the top holding at 14% of the fund, has come off sharply in recent days. Barclays cut the stock to underweight, noting that valuation had run ahead of fundamentals.  Shares of AST are down 20% in the last five days but the fund remains +15% for the month. Other main holdings include Rocket Lab, ViaSat, Planet Labs and MDA Space Ltd.

Finally, looking at country performance it’s no surprise to see a South Korean-focused ETF among the top performers as the KOSPI is the best-performing major national equity index this year. There are many Korean equity ETFs but top of the list is the HSBC MSCI Korea Capped ETF. It’s about 30% Samsung but still offers diversified exposure to Korean stocks.

 

 

Quarterly Outlook

01 /

  • Q4 Outlook for Investors: Diversify like it’s 2025 – don’t fall for déjà vu

    Quarterly Outlook

    Q4 Outlook for Investors: Diversify like it’s 2025 – don’t fall for déjà vu

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q4 Outlook for Traders: The Fed is back in easing mode. Is this time different?

    Quarterly Outlook

    Q4 Outlook for Traders: The Fed is back in easing mode. Is this time different?

    John J. Hardy

    Global Head of Macro Strategy

    The Fed launched a new easing cycle in late Q3. Will this cycle now play out like 2000 or 2007?
  • Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Quarterly Outlook

    Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    Quarterly Outlook

    Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    John J. Hardy

    Global Head of Macro Strategy

    After the chaos of Q2, the quarter ahead should get a bit more clarity on how Trump 2.0 is impacting...
  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details. Past Performance is not indicative of future results.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992